StonvexLoading…
StonvexStonvexStonvexCore line items from ENSG's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $5.03B | $4.24B | $3.71B | $3.03B |
Operating Income | $425.31M | $358.30M | $255.37M | $296.82M |
Net Income | $343.97M | $297.97M | $209.40M | $224.68M |
EPS (Diluted) | $5.84 | $5.12 | $3.65 | $3.95 |
Total Assets | $5.46B | $4.67B | $4.18B | $3.45B |
Total Liabilities | $3.23B | $2.83B | $2.68B | $2.20B |
Cash & Equivalents | $503.88M | $464.60M | $509.63M | $316.27M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 58.09M | 57.44M | 56.60M | 55.66M |